Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function

Han Seok Ko, Yunjong Lee, Joo Ho Shin, Senthilkumar S. Karuppagounder, Bharathi Shrikanth Gadad, Anthony J. Koleske, Olga Pletnikova, Juan C. Troncoso, Valina L. Dawson, Ted M. Dawson

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Mutations in PARK2/Parkin, which encodes a ubiquitin E3 ligase, cause autosomal recessive Parkinsondisease (PD). Here we show that the nonreceptor tyrosine kinase c-Abl phosphorylates tyrosine 143 of parkin, inhibiting parkin's ubiquitin E3 ligase activity and protective function. c-Abl is activated by dopaminergic stress and by dopaminergic neurotoxins, 1-methyl-4-phenylpyridinium (MPP+) in vitro and in vivo by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), leading to parkin inactivation, accumulation of the parkin substrates aminoacyl-tRNA synthetase-interacting multifunctional protein type 2 (AIMP2) (p38/JTV-1) and fuse-binding protein 1 (FBP1), and cell death. STI-571, a c-Abl-family kinase inhibitor, prevents the phosphorylation of parkin, maintaining parkin in a catalytically active and protective state. STI-571's protective effects require parkin, as shRNA knockdown of parkin prevents STI-571 protection. Conditional knockout of c-Abl in the nervous system also prevents the phosphorylation of parkin, the accumulation of its substrates, and subsequent neurotoxicity in response to MPTP intoxication. In human postmortem PD brain, c-Abl is active, parkin is tyrosine-phosphorylated, and AIMP2 and FBP1 accumulate in the substantia nigra and striatum. Thus, tyrosine phosphorylation of parkin by c-Abl is a major post-translational modification that inhibits parkin function, possibly contributing to pathogenesis of sporadic PD. Moreover, inhibition of c-Abl may be a neuroprotective approach in the treatment of PD.

Original languageEnglish (US)
Pages (from-to)16691-16696
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume107
Issue number38
DOIs
StatePublished - Sep 21 2010

Fingerprint

Proto-Oncogene Proteins c-abl
Ubiquitination
Protein-Tyrosine Kinases
Tyrosine
Amino Acyl-tRNA Synthetases
Ubiquitin-Protein Ligases
Phosphorylation
Carrier Proteins
1-Methyl-4-phenylpyridinium
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Neurotoxins
Substantia Nigra
Post Translational Protein Processing
Nervous System
Small Interfering RNA
Proteins
Cell Death
Phosphotransferases
Mutation
Brain

Keywords

  • AIMP2
  • Parkinson disease
  • STI-571
  • Ubiquitin

ASJC Scopus subject areas

  • General
  • Medicine(all)

Cite this

Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. / Ko, Han Seok; Lee, Yunjong; Shin, Joo Ho; Karuppagounder, Senthilkumar S.; Gadad, Bharathi Shrikanth; Koleske, Anthony J.; Pletnikova, Olga; Troncoso, Juan C.; Dawson, Valina L.; Dawson, Ted M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 38, 21.09.2010, p. 16691-16696.

Research output: Contribution to journalArticle

Ko, HS, Lee, Y, Shin, JH, Karuppagounder, SS, Gadad, BS, Koleske, AJ, Pletnikova, O, Troncoso, JC, Dawson, VL & Dawson, TM 2010, 'Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function', Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 38, pp. 16691-16696. https://doi.org/10.1073/pnas.1006083107
Ko, Han Seok ; Lee, Yunjong ; Shin, Joo Ho ; Karuppagounder, Senthilkumar S. ; Gadad, Bharathi Shrikanth ; Koleske, Anthony J. ; Pletnikova, Olga ; Troncoso, Juan C. ; Dawson, Valina L. ; Dawson, Ted M. / Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. In: Proceedings of the National Academy of Sciences of the United States of America. 2010 ; Vol. 107, No. 38. pp. 16691-16696.
@article{213002904afd4fcd8e4c7817befda251,
title = "Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function",
abstract = "Mutations in PARK2/Parkin, which encodes a ubiquitin E3 ligase, cause autosomal recessive Parkinsondisease (PD). Here we show that the nonreceptor tyrosine kinase c-Abl phosphorylates tyrosine 143 of parkin, inhibiting parkin's ubiquitin E3 ligase activity and protective function. c-Abl is activated by dopaminergic stress and by dopaminergic neurotoxins, 1-methyl-4-phenylpyridinium (MPP+) in vitro and in vivo by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), leading to parkin inactivation, accumulation of the parkin substrates aminoacyl-tRNA synthetase-interacting multifunctional protein type 2 (AIMP2) (p38/JTV-1) and fuse-binding protein 1 (FBP1), and cell death. STI-571, a c-Abl-family kinase inhibitor, prevents the phosphorylation of parkin, maintaining parkin in a catalytically active and protective state. STI-571's protective effects require parkin, as shRNA knockdown of parkin prevents STI-571 protection. Conditional knockout of c-Abl in the nervous system also prevents the phosphorylation of parkin, the accumulation of its substrates, and subsequent neurotoxicity in response to MPTP intoxication. In human postmortem PD brain, c-Abl is active, parkin is tyrosine-phosphorylated, and AIMP2 and FBP1 accumulate in the substantia nigra and striatum. Thus, tyrosine phosphorylation of parkin by c-Abl is a major post-translational modification that inhibits parkin function, possibly contributing to pathogenesis of sporadic PD. Moreover, inhibition of c-Abl may be a neuroprotective approach in the treatment of PD.",
keywords = "AIMP2, Parkinson disease, STI-571, Ubiquitin",
author = "Ko, {Han Seok} and Yunjong Lee and Shin, {Joo Ho} and Karuppagounder, {Senthilkumar S.} and Gadad, {Bharathi Shrikanth} and Koleske, {Anthony J.} and Olga Pletnikova and Troncoso, {Juan C.} and Dawson, {Valina L.} and Dawson, {Ted M.}",
year = "2010",
month = "9",
day = "21",
doi = "10.1073/pnas.1006083107",
language = "English (US)",
volume = "107",
pages = "16691--16696",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "38",

}

TY - JOUR

T1 - Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function

AU - Ko, Han Seok

AU - Lee, Yunjong

AU - Shin, Joo Ho

AU - Karuppagounder, Senthilkumar S.

AU - Gadad, Bharathi Shrikanth

AU - Koleske, Anthony J.

AU - Pletnikova, Olga

AU - Troncoso, Juan C.

AU - Dawson, Valina L.

AU - Dawson, Ted M.

PY - 2010/9/21

Y1 - 2010/9/21

N2 - Mutations in PARK2/Parkin, which encodes a ubiquitin E3 ligase, cause autosomal recessive Parkinsondisease (PD). Here we show that the nonreceptor tyrosine kinase c-Abl phosphorylates tyrosine 143 of parkin, inhibiting parkin's ubiquitin E3 ligase activity and protective function. c-Abl is activated by dopaminergic stress and by dopaminergic neurotoxins, 1-methyl-4-phenylpyridinium (MPP+) in vitro and in vivo by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), leading to parkin inactivation, accumulation of the parkin substrates aminoacyl-tRNA synthetase-interacting multifunctional protein type 2 (AIMP2) (p38/JTV-1) and fuse-binding protein 1 (FBP1), and cell death. STI-571, a c-Abl-family kinase inhibitor, prevents the phosphorylation of parkin, maintaining parkin in a catalytically active and protective state. STI-571's protective effects require parkin, as shRNA knockdown of parkin prevents STI-571 protection. Conditional knockout of c-Abl in the nervous system also prevents the phosphorylation of parkin, the accumulation of its substrates, and subsequent neurotoxicity in response to MPTP intoxication. In human postmortem PD brain, c-Abl is active, parkin is tyrosine-phosphorylated, and AIMP2 and FBP1 accumulate in the substantia nigra and striatum. Thus, tyrosine phosphorylation of parkin by c-Abl is a major post-translational modification that inhibits parkin function, possibly contributing to pathogenesis of sporadic PD. Moreover, inhibition of c-Abl may be a neuroprotective approach in the treatment of PD.

AB - Mutations in PARK2/Parkin, which encodes a ubiquitin E3 ligase, cause autosomal recessive Parkinsondisease (PD). Here we show that the nonreceptor tyrosine kinase c-Abl phosphorylates tyrosine 143 of parkin, inhibiting parkin's ubiquitin E3 ligase activity and protective function. c-Abl is activated by dopaminergic stress and by dopaminergic neurotoxins, 1-methyl-4-phenylpyridinium (MPP+) in vitro and in vivo by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), leading to parkin inactivation, accumulation of the parkin substrates aminoacyl-tRNA synthetase-interacting multifunctional protein type 2 (AIMP2) (p38/JTV-1) and fuse-binding protein 1 (FBP1), and cell death. STI-571, a c-Abl-family kinase inhibitor, prevents the phosphorylation of parkin, maintaining parkin in a catalytically active and protective state. STI-571's protective effects require parkin, as shRNA knockdown of parkin prevents STI-571 protection. Conditional knockout of c-Abl in the nervous system also prevents the phosphorylation of parkin, the accumulation of its substrates, and subsequent neurotoxicity in response to MPTP intoxication. In human postmortem PD brain, c-Abl is active, parkin is tyrosine-phosphorylated, and AIMP2 and FBP1 accumulate in the substantia nigra and striatum. Thus, tyrosine phosphorylation of parkin by c-Abl is a major post-translational modification that inhibits parkin function, possibly contributing to pathogenesis of sporadic PD. Moreover, inhibition of c-Abl may be a neuroprotective approach in the treatment of PD.

KW - AIMP2

KW - Parkinson disease

KW - STI-571

KW - Ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=78049275348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049275348&partnerID=8YFLogxK

U2 - 10.1073/pnas.1006083107

DO - 10.1073/pnas.1006083107

M3 - Article

C2 - 20823226

AN - SCOPUS:78049275348

VL - 107

SP - 16691

EP - 16696

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 38

ER -